JP6010136B2 - ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物 - Google Patents

ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物 Download PDF

Info

Publication number
JP6010136B2
JP6010136B2 JP2014548657A JP2014548657A JP6010136B2 JP 6010136 B2 JP6010136 B2 JP 6010136B2 JP 2014548657 A JP2014548657 A JP 2014548657A JP 2014548657 A JP2014548657 A JP 2014548657A JP 6010136 B2 JP6010136 B2 JP 6010136B2
Authority
JP
Japan
Prior art keywords
cells
cell
culture
cytokine
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014548657A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502756A (ja
Inventor
ボギョン ミン
ボギョン ミン
ハナ チョイ
ハナ チョイ
オクジェ リム
オクジェ リム
ジュンヒョン ヘル
ジュンヒョン ヘル
サンミ カン
サンミ カン
ウンギョン イ
ウンギョン イ
ヘジン チュン
ヘジン チュン
ユギョン ファン
ユギョン ファン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GC Cell Corp
Original Assignee
Green Cross Lab Cell Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Lab Cell Corp filed Critical Green Cross Lab Cell Corp
Publication of JP2015502756A publication Critical patent/JP2015502756A/ja
Application granted granted Critical
Publication of JP6010136B2 publication Critical patent/JP6010136B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/16—Physical preservation processes
    • A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/47—Brain; Nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1157—Monocytes, macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dentistry (AREA)
  • Reproductive Health (AREA)
  • Environmental Sciences (AREA)
  • Urology & Nephrology (AREA)
JP2014548657A 2011-12-22 2012-12-18 ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物 Active JP6010136B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2011-0140361 2011-12-22
KR20110140361 2011-12-22
PCT/KR2012/011114 WO2013094988A1 (en) 2011-12-22 2012-12-18 Method for producing natural killer cells, natural killer cells produced thereby, and composition for treating cancers and infectious diseases containing the same

Publications (2)

Publication Number Publication Date
JP2015502756A JP2015502756A (ja) 2015-01-29
JP6010136B2 true JP6010136B2 (ja) 2016-10-19

Family

ID=48668805

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014548657A Active JP6010136B2 (ja) 2011-12-22 2012-12-18 ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物

Country Status (9)

Country Link
US (1) US9834753B2 (enExample)
EP (1) EP2794859B1 (enExample)
JP (1) JP6010136B2 (enExample)
KR (1) KR101644984B1 (enExample)
CN (1) CN104204194B (enExample)
AU (1) AU2012354438B2 (enExample)
ES (1) ES2652666T3 (enExample)
NO (1) NO2794859T3 (enExample)
WO (1) WO2013094988A1 (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103923879B (zh) * 2014-04-29 2016-03-30 湖北华赛生物医药技术有限公司 一种nk细胞因子混合物的制备方法及其应用
KR101697473B1 (ko) * 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
CN104593324B (zh) * 2014-11-28 2018-04-13 广州赛莱拉干细胞科技股份有限公司 一种自然杀伤细胞的培养基及自然杀伤细胞的扩增培养方法
KR101706524B1 (ko) * 2014-12-03 2017-02-14 주식회사 녹십자랩셀 안정성 높은 자연살해세포의 효율적인 제조방법
WO2016122014A1 (ko) * 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
US12398371B2 (en) 2015-01-27 2025-08-26 Korea Research Institute Of Bioscience Method for mass producing natural killer cell and use of natural killer cell obtained by the method as anti-cancer agent
CN104789527B (zh) * 2015-05-15 2018-05-29 江苏杰晟生物科技有限公司 一种自体自然杀伤细胞鸡尾酒式培养的制备方法及其试剂盒产品
KR101909879B1 (ko) * 2015-06-24 2018-10-19 주식회사 차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
WO2016209021A1 (ko) * 2015-06-24 2016-12-29 주식회사 차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
JP6073417B2 (ja) * 2015-06-26 2017-02-01 チャ バイオテック カンパニー リミテッド 自然殺害細胞増殖方法、及び自然殺害細胞増殖用の組成物
WO2017003153A1 (ko) * 2015-06-29 2017-01-05 주식회사 녹십자랩셀 제대혈 단핵세포 또는 이로부터 유래된 세포로부터 자연살해세포를 제조하는 방법
EP3138905A1 (en) * 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
EP3389695A4 (en) * 2015-12-16 2019-10-09 The Walter and Eliza Hall Institute of Medical Research INHIBITION OF CYTOKININDUCED SH2 PROTEIN IN NK CELLS
EP3412149A4 (en) * 2016-02-01 2019-09-18 Green Cross Lab Cell Corporation COMPOSITION OF A MEDIUM FOR CRYOCONIZING CELLS AND USES THEREOF
CN109071679B (zh) * 2016-02-05 2023-07-28 华盛顿大学 用于靶向的细胞因子递送的组合物和方法
KR101683614B1 (ko) * 2016-02-15 2016-12-07 신동혁 Nk세포배양용 배지첨가키트 및 상기 키트를 이용한 nk세포배양방법
CN105754942A (zh) * 2016-05-18 2016-07-13 天津普瑞赛尔生物科技有限公司 一种体外扩增nk细胞的方法及其获得的nk细胞
CN105925527A (zh) * 2016-05-19 2016-09-07 成都百赛泰科生物科技有限公司 一种用于制备nk细胞的试剂盒及其应用方法
CN107686828A (zh) * 2016-08-04 2018-02-13 英普乐孚生物技术(上海)有限公司 一种nk细胞无血清培养基
CN106434554B (zh) * 2016-08-31 2019-07-26 北京同立海源生物科技有限公司 Nk细胞的制备方法
US10300089B2 (en) * 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
CN109983120A (zh) * 2016-11-14 2019-07-05 白雁生物技术公司 含有外源线粒体的天然杀伤细胞和含有其的药物组合物
CN106834227B (zh) * 2016-12-26 2020-01-24 深圳精准医疗科技有限公司 自然杀伤细胞的体外纯化方法
EP3567049A4 (en) 2016-12-28 2020-08-26 Green Cross Lab Cell Corporation CHEMERICAL ANTIGENIC RECEPTOR AND NATURAL KILLER CELLS EXPRESSING THE SAME
EP3399027A1 (en) * 2017-05-04 2018-11-07 Medizinische Hochschule Hannover Stem-cell derived myeloid cells, generation and use thereof
WO2018217064A2 (ko) 2017-05-26 2018-11-29 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 자연살해세포의 배양방법
CN107267463A (zh) * 2017-08-23 2017-10-20 安徽惠恩生物科技股份有限公司 一种针对乳腺癌的Car‑NK细胞制备方法
CN107595865B (zh) * 2017-09-25 2018-08-14 徐州佳生医药科技有限公司 一种ccr5表达促进剂及在制备促进nk细胞穿透血脑屏障的药物中的应用
US12116417B2 (en) 2017-11-14 2024-10-15 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
US11649294B2 (en) 2017-11-14 2023-05-16 GC Cell Corporation Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
KR102265437B1 (ko) 2017-11-24 2021-06-15 의료법인 성광의료재단 Nk 배양용 조성물 및 이를 이용하여 nk 세포를 배양하는 방법
KR102014467B1 (ko) * 2017-12-14 2019-08-26 (주)녹십자웰빙 아토피성 피부염, 탈모, 상처 또는 피부 주름의 개선용 화장료 조성물 및 약학 조성물
US20210040451A1 (en) * 2018-01-31 2021-02-11 Nantkwest, Inc. Use of 5% human albumin in wash and harvest media
AU2019215034C1 (en) 2018-02-01 2022-01-06 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
EP3755349A4 (en) 2018-02-21 2021-11-17 Board of Regents, The University of Texas System PROCESS FOR ACTIVATION AND EXPANSION OF NATURAL KILLER CELLS AND THEIR USES
KR102232321B1 (ko) * 2018-03-23 2021-03-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
WO2019182392A1 (ko) 2018-03-23 2019-09-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
WO2019213610A1 (en) * 2018-05-03 2019-11-07 Board Of Regents, The University Of Texas System Natural killer cells engineered to express chimeric antigen receptors with immune checkpoint blockade
CN108815186A (zh) * 2018-06-14 2018-11-16 上海鸣大生物科技有限公司 一种治疗hpv持续感染引起疾病的药物及制备方法与应用
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
SG11202104662UA (en) 2018-11-14 2021-06-29 Green Cross Lab Cell Corp Method for culturing cord blood-derived natural killer cells using transformed t-cells
CN109762785B (zh) * 2018-12-10 2022-06-24 苏州近岸蛋白质科技股份有限公司 一种高效应用于人nk细胞非滋养层体外培养的方法
KR102419960B1 (ko) * 2019-03-15 2022-07-13 (주) 테라베스트 세포 조성물, 이의 제조 방법 및 이를 포함하는 아토피 예방 또는 치료용 약학 조성물
KR102137954B1 (ko) * 2019-05-16 2020-07-27 (주)녹십자셀 사이토카인 유도 살해세포를 포함하는 활성화 림프구 및 이의 제조 방법
CN110305843B (zh) * 2019-07-12 2020-06-02 赛德特生物科技开发有限公司 可以改善自身免疫性疾病的免疫细胞及其制备方法与应用
PL4063491T3 (pl) * 2019-11-20 2025-03-31 Gi Cell, Inc. Kompozycja do hodowli komórek naturalnych zabójców i sposób otrzymywania komórek naturalnych zabójców z jej zastosowaniem
JP2023505102A (ja) * 2019-11-29 2023-02-08 エヌケーマックス カンパニー リミテッド ナチュラルキラー細胞を製造する方法およびその組成物
KR102111283B1 (ko) 2019-12-12 2020-05-15 주식회사 이뮤니스바이오 면역세포의 진탕 배양 방법
US12486492B2 (en) 2020-03-05 2025-12-02 Korea Research Institute Of Bioscience Method for producing memory-like NK cells with ability to express higher levels of NCRs, cytotoxicity, and IFN-γ than NK cells in human peripheral blood
US20230096410A1 (en) 2020-03-06 2023-03-30 Sorrento Therapeutics, Inc. Innate Immunity Killer Cells Targeting PSMA Positive Tumor Cells
JP2023517220A (ja) * 2020-03-11 2023-04-24 リサーチ インスティテュート アット ネイションワイド チルドレンズ ホスピタル 微生物感染症の治療のためのｎｋ細胞およびそれらの使用
CN111690610A (zh) * 2020-07-22 2020-09-22 暨赛再生医学科技有限公司 一种高效诱导培养制备自然杀伤性nk细胞的方法
KR102736008B1 (ko) * 2020-09-15 2024-12-03 주식회사 티에스바이오 고순도 및 고효율의 자연살해세포 제조방법 및 이의 용도
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
KR20240063899A (ko) * 2021-09-08 2024-05-10 가부시키가이샤 가이아바이오메디신 세포의 처리 방법
KR20230039789A (ko) * 2021-09-10 2023-03-21 한국생명공학연구원 자연살해세포의 제조방법 및 이의 감염성 질환 예방 또는 치료 용도
US20250346649A1 (en) 2021-11-05 2025-11-13 St. Jude Children's Research Hospital, Inc. Zip cytokine receptors
WO2023147347A2 (en) * 2022-01-25 2023-08-03 The Regents Of The University Of California Crispr-mediated deletion of fli1 in nk cells
US20250312450A1 (en) 2022-06-08 2025-10-09 St. Jude Children's Research Hospital, Inc. Disruption of kdm4a in t cells to enhance immunotherapy
WO2024059787A1 (en) 2022-09-16 2024-03-21 St. Jude Children's Research Hospital, Inc. Disruption of asxl1 in t cells to enhance immunotherapy
CN118546880A (zh) * 2023-02-24 2024-08-27 士泽生物医药（苏州）有限公司 诱导干细胞分化为nk细胞的试剂盒及其应用以及nk细胞联合tmz在治疗tmz耐药型gbm中的应用
CN118109410B (zh) * 2024-04-26 2024-07-16 赛奥斯博生物科技(北京)有限公司 一种自然杀伤细胞外泌体的制备方法及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766601A (en) * 1990-08-08 1998-06-16 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
WO1997005239A1 (en) * 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
WO1997032970A1 (en) * 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ('modified-rem') for in vitro propagation of t lymphocytes
EP0947581A4 (en) * 1996-08-08 2004-07-28 Mitsubishi Pharma Corp CULTURAL MEDIUM AND ITS USE.
US20030068306A1 (en) * 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
WO2005007116A2 (en) * 2003-07-18 2005-01-27 Valeocyte Therapies Llc Artificial antigen presenting cell devices
KR20080008060A (ko) 2006-07-19 2008-01-23 전남대학교산학협력단 자연살해세포의 제조 방법
JP2010501173A (ja) * 2006-08-23 2010-01-21 バイネックス カンパニー リミテッド 免疫治療用活性化リンパ球の製造方法
CN101302491B (zh) 2007-05-09 2011-09-14 王歈 高效扩增活化淋巴细胞的方法和培养系统
JP4953403B2 (ja) * 2007-11-05 2012-06-13 恒雄 倉持 がん免疫療法用細胞の製造方法
KR101035556B1 (ko) 2008-05-22 2011-05-23 재단법인 목암생명공학연구소 자연살해세포의 제조방법, 이러한 방법에 의해 제조된자연살해세포, 및 이를 유효성분으로 포함하는 고형 종양치료용 조성물
KR20090127974A (ko) * 2008-06-10 2009-12-15 주식회사 엔케이바이오 자기활성화 림프구 배양용 배지 조성물
KR101043588B1 (ko) 2008-07-25 2011-06-22 재단법인 철원플라즈마 산업기술연구원 내 플라즈마 세라믹 코팅막 형성방법
KR101133185B1 (ko) * 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
CN102428173B (zh) 2009-03-26 2014-07-30 细胞维护北欧制药公司 Nk细胞的扩增
US9062287B2 (en) * 2009-09-11 2015-06-23 Takara Bio Inc. Process for production of natural killer cells
ES2851601T3 (es) * 2009-12-29 2021-09-08 Gamida Cell Ltd Métodos para mejorar la proliferación y actividad de los linfocitos citolíticos naturales
WO2012146702A1 (en) * 2011-04-28 2012-11-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing accessory cells and uses thereof for preparing activated nk cells

Also Published As

Publication number Publication date
AU2012354438A1 (en) 2014-07-10
CN104204194B (zh) 2018-08-03
JP2015502756A (ja) 2015-01-29
KR101644984B1 (ko) 2016-08-12
AU2012354438B2 (en) 2016-03-31
ES2652666T3 (es) 2018-02-05
CN104204194A (zh) 2014-12-10
EP2794859B1 (en) 2017-09-20
EP2794859A4 (en) 2015-05-27
KR20140123503A (ko) 2014-10-22
NO2794859T3 (enExample) 2018-02-17
EP2794859A1 (en) 2014-10-29
WO2013094988A1 (en) 2013-06-27
US20150118207A1 (en) 2015-04-30
US9834753B2 (en) 2017-12-05

Similar Documents

Publication Publication Date Title
JP6010136B2 (ja) ナチュラルキラー細胞の製造方法、その方法により製造されたナチュラルキラー細胞、並びにそれを含む腫瘍及び感染性疾患治療用組成物
US20240050478A1 (en) Method for Culturing Natural Killer Cells Using T Cells
ES2877108T3 (es) Activación de linfocitos infiltrantes de médula en condiciones hipóxicas alternantes con normóxicas
CN104789527B (zh) 一种自体自然杀伤细胞鸡尾酒式培养的制备方法及其试剂盒产品
US20210147803A1 (en) Method for producing natural killer cells
AU2006288348B2 (en) Method for activation treatment of antigen-presenting cell
US10385315B2 (en) Cells expressing Th1 characteristics and cytolytic properties
TWI764896B (zh) 有效率的ｎｋｔ細胞活化技術
TW200908988A (en) Therapeutic agent for cancer
MX2009001269A (es) Metodo de proliferacion de celulas asesinas activadas por linfocina.
KR101799986B1 (ko) T 세포를 이용한 자연살해세포의 배양방법

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160823

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160915

R150 Certificate of patent or registration of utility model

Ref document number: 6010136

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250